• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性脑缺血患者认知障碍的诊断与治疗:俄罗斯观察性项目DIAMANT的结果

[Diagnosis and treatment of cognitive impairment in patients with chronic cerebral ischemia: the results of observational Russian program DIAMANT].

作者信息

Parfenov V A, Zhivolupov S A, Nikulina K V, Poverennova I E, Lapatuhin V G, Zhestikova M G, Zhukova N G, Glazunov A B

机构信息

Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia.

St Petersburg Medical Academy, St Petersburg, Russia.

出版信息

Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(6):15-23. doi: 10.17116/jnevro20181186115.

DOI:10.17116/jnevro20181186115
PMID:30040796
Abstract

AIM

To investigate the efficacy of divaza in outpatients with cognitive disorders and chronic brain ischemia (CBI).

MATERIAL AND METHODS

The non-interventional observational program included the data of 2583 outpatients with CBI from 30 cities (8 federal okrugs of the Russian Federation) who were on outpatient neurological treatment and received divaza in a dose of 2 tablets three times a day from Oct 2016 to Jan 2017. Cognitive functions were evaluated using the MoCA scale before and after 3 months of treatment.

RESULTS AND CONCLUSION

Cognitive disorders were identified in 90.7% of patients (<26 MoCA scores). After treatment, the mean MoCA score increased from 19.58±5.13 to 23.99±4.21 (p<0.0001), the number of patients with normal cognitive functions rate (≥26 scores) increased from 9.3 to 41.3%, the number of patients with marked cognitive impairment decreased. The drug was well-tolerated by old and very old patients, adverse events were observed rarely (0.6% of cases). The majority of doctors (88.4%) noticed the effect of divaza as significant improvement or improvement, and 89.6% of patients valued the effect to be excellent or good. The use of divaza, the drug with endothelioprotective and nootropic effects, is pathogenetically justified and promising in patients with cognitive disorders of vascular etiology.

摘要

目的

研究地伐西匹对认知障碍和慢性脑缺血(CBI)门诊患者的疗效。

材料与方法

非干预性观察项目纳入了来自30个城市(俄罗斯联邦8个联邦区)的2583例接受门诊神经治疗的CBI门诊患者的数据,这些患者在2016年10月至2017年1月期间每天服用3次、每次2片地伐西匹。在治疗3个月前后使用蒙特利尔认知评估量表(MoCA)评估认知功能。

结果与结论

90.7%的患者存在认知障碍(MoCA评分<26分)。治疗后,MoCA平均评分从19.58±5.13提高到23.99±4.21(p<0.0001),认知功能正常(≥26分)的患者比例从9.3%增加到41.3%,明显认知障碍的患者数量减少。老年和高龄患者对该药物耐受性良好,不良事件发生率很低(0.6%)。大多数医生(88.4%)注意到地伐西匹的效果显著改善或有所改善,89.6%的患者认为效果极佳或良好。对于血管病因导致认知障碍的患者,使用具有内皮保护和促智作用的地伐西匹在发病机制上是合理的,且前景广阔。

相似文献

1
[Diagnosis and treatment of cognitive impairment in patients with chronic cerebral ischemia: the results of observational Russian program DIAMANT].慢性脑缺血患者认知障碍的诊断与治疗:俄罗斯观察性项目DIAMANT的结果
Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(6):15-23. doi: 10.17116/jnevro20181186115.
2
Treatment of Cognitive Impairment and the Role of Demographic Factors in Disease Progression: The Final Results of the Russian Observational Program "DIAMANT".认知障碍的治疗及人口统计学因素在疾病进展中的作用:俄罗斯观察性研究计划“DIAMANT”的最终结果。
Eur Neurol. 2020;83(6):591-601. doi: 10.1159/000508184. Epub 2020 Nov 17.
3
Efficacy and Safety of Divaza for the Correction of Oxidative Disturbances in Patients with Cerebral Atherosclerosis: A Randomized Controlled Trial.Divaza 治疗脑动脉硬化患者氧化应激紊乱的疗效和安全性:一项随机对照试验。
Cerebrovasc Dis. 2021;50(4):472-482. doi: 10.1159/000515233. Epub 2021 May 27.
4
[The assessment of the efficacy of Ethoxidol treatment in patients with chronic cerebral ischemia].[乙氧醇治疗慢性脑缺血患者的疗效评估]
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(9):31-37. doi: 10.17116/jnevro202112109131.
5
[Neurometabolic therapy of mild cognitive impairment in patients with chronic cerebral ischemia].[慢性脑缺血患者轻度认知障碍的神经代谢治疗]
Zh Nevrol Psikhiatr Im S S Korsakova. 2024;124(3):42-51. doi: 10.17116/jnevro202412403142.
6
[An effect of complex therapy on cognitive impairment in patients with chronic cerebral ischemia].
Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(2):23-27. doi: 10.17116/jnevro201911902123.
7
[Therapy of moderate cognitive impairment and asthenia in patients with cerebrovascular pathology: results of a prospective observational study].[脑血管病变患者中度认知障碍和虚弱的治疗:一项前瞻性观察研究的结果]
Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(8):88-94. doi: 10.17116/jnevro202212208188.
8
[Multicenter observational program for evaluation of the effectiveness of the recognan (citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology].[多中心观察项目:评估可尼丁(胞磷胆碱)对慢性脑血管病变患者认知障碍的纠正效果]
Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(8):39-43. doi: 10.17116/jnevro20171178139-43.
9
[Divasa in the treatment and prevention of cerebrovascular diseases].[Divasa在脑血管疾病的治疗与预防中]
Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(12):111-115. doi: 10.17116/jnevro2017117121111-115.
10
[Efficacy and safety of the drug Cellex for the treatment of patients with cognitive impairment with chronic cerebral ischemia - results of a multicenter randomized double-blind placebo-controlled clinical trial].[药物Cellex治疗慢性脑缺血性认知障碍患者的疗效与安全性——一项多中心随机双盲安慰剂对照临床试验的结果]
Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(5):108-116. doi: 10.17116/jnevro2023123051108.

引用本文的文献

1
Vascular cognitive impairment: pathophysiological mechanisms, insights into structural basis, and perspectives in specific treatments.血管性认知障碍:病理生理机制、对结构基础的见解及特定治疗的展望
Neuropsychiatr Dis Treat. 2019 May 21;15:1381-1402. doi: 10.2147/NDT.S197032. eCollection 2019.